July 1 (Reuters) - Recce Pharmaceuticals Ltd (RCE) :
- RECCE PHARMACEUTICALS REPORTS POSITIVE DATA FROM PHASE I/II URINARY TRACT INFECTION (UTI) / UROSEPSIS RAPID INFUSION TRIAL OF RECCE® 327
- RECCE PHARMACEUTICALS LTD: NO SERIOUS ADVERSE EVENTS AND CLINICALLY SIGNIFICANT CHANGES OBSERVED, REINFORCING SAFETY PROFILE OF R327
- RECCE PHARMACEUTICALS LTD: ON TRACK TO INITIATE PHASE II TRIAL OF R327 IN PATIENTS WITH URINARY TRACT INFECTIONS IN H2 2024
News: RCE Recce Pharmaceuticals Says No Serious Adverse Events And Clinically Significant Changes...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.005(1.22%) |
Mkt cap ! $120.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 43.0¢ | 40.0¢ | $53.73K | 128.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 45877 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 61604 | 2 |
View Market Depth
| Last trade - 16.10pm 12/08/2025 (20 minute delay) ? |
| RCE (ASX) Chart |